Fig.1 Percent change from baseline at 6 and 12 months for all outline mreaures. Error bars±1 SD.Single astrisk denotes significant difference from baseline and placebo (p<0.05 level);double asterisk denotes significant differences from baseline,6-month measure, and placebo(p<0.05 level)
After 6 months of lutein and Zeaxanthin 24mg intake, MOPD, DG(glare tolerance) and PSR(speed of recovery after glare) were significantly improved.
After 6 moths of lutein Zeaxanthin 24 mg intake, headache,eye fatigue and sleep disorders were significantly improved.
Table 2. MPOD (OD Units) Response by Week and Dose (Mean ± SD).
|Bseline||Week 2||Week 4||Week 6||Week 8||Week 10||Week 12|
|Group Ⅰ, placebo||0.44±0.29||0.45±0.27||0.48±0.33||0.48±0.34||0.54±0.40||0.49±0.33||0.47±0.29|
|Group Ⅱ,6mgL/1mg Zi||0.73±0.15||0.75±0.11||0.75±0.12||0.79±0.10||0.81±0.13||0.82±0.14||0.82±0.11|
|Group Ⅲ,10mgL/2mg Zi||0.42±0.25||0.45±0.24||0.49±0.26||0.51±0.29||0.54±0.33||0.54±0.31||0.56±0.31|
|Group Ⅳ,20mgL/4mg Zi||0.43±0.15||0.45±0.15||0.48±0.16||0.48±0.18||0.50±0.19||0.57±0.17||0.55±0.17|
Eye and Vision (2016)3:30 l Foods (2017)6:47
Experimental Eye Researth (2016)151:1 l New Frontiers in Opthalmoiogy (2016)2:4